Consuming genomes

Scientific and social innovation in direct-to-consumer genetic testing

Margaret Curnutte, Giuseppe Testa

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Since 2006 companies in the US have started to offer direct-to-consumer (DTC) genetic testing for a variety of diseases and traits. Recently, the activities of 23andMe and Navigenics, the two leading providers of DTC genetic services, have come under the scrutiny of various regulators and institutions, including the Food and Drug Administration (FDA) and the House Committee on Energy and Commerce and, in 2008, the California and New York Departments of Health. In this work we first situate this DTC innovation within the historical trajectory of gene testing as it developed in the context of clinical medicine around the three key criteria of analytic validity, clinical validity, and clinical utility. We then analyze the recent encounters between DTC providers and regulators to identify the key scientific and discursive resources that are being employed to position this innovation with respect to analytic validity, clinical validity, and clinical utility. Our empirical analysis of a rich set of primary sources (including websites, policy documents, and interviews) shows that the emergence of DTC gene testing is a conspicuous instance of co-production: a new kind of genetic knowledge and a new kind of biological citizenship is being articulated around the figure of the genetic consumer.

Original languageEnglish
Pages (from-to)159-181
Number of pages23
JournalNew Genetics and Society
Volume31
Issue number2
DOIs
Publication statusPublished - Jun 1 2012

Fingerprint

Genetic Testing
Genome
Genetic Services
innovation
Clinical Medicine
United States Food and Drug Administration
Genes
Interviews
Health
coproduction
commerce
Direct-To-Consumer Screening and Testing
website
citizenship
medicine
Disease
energy
interview
health
resources

Keywords

  • analytic validity
  • clinical utility
  • clinical validity
  • direct-to-consumer
  • genetic testing

ASJC Scopus subject areas

  • Health Policy
  • Issues, ethics and legal aspects
  • Health(social science)
  • Genetics

Cite this

Consuming genomes : Scientific and social innovation in direct-to-consumer genetic testing. / Curnutte, Margaret; Testa, Giuseppe.

In: New Genetics and Society, Vol. 31, No. 2, 01.06.2012, p. 159-181.

Research output: Contribution to journalArticle

@article{d2259efecab74fe99b8fe8a0f3972d3a,
title = "Consuming genomes: Scientific and social innovation in direct-to-consumer genetic testing",
abstract = "Since 2006 companies in the US have started to offer direct-to-consumer (DTC) genetic testing for a variety of diseases and traits. Recently, the activities of 23andMe and Navigenics, the two leading providers of DTC genetic services, have come under the scrutiny of various regulators and institutions, including the Food and Drug Administration (FDA) and the House Committee on Energy and Commerce and, in 2008, the California and New York Departments of Health. In this work we first situate this DTC innovation within the historical trajectory of gene testing as it developed in the context of clinical medicine around the three key criteria of analytic validity, clinical validity, and clinical utility. We then analyze the recent encounters between DTC providers and regulators to identify the key scientific and discursive resources that are being employed to position this innovation with respect to analytic validity, clinical validity, and clinical utility. Our empirical analysis of a rich set of primary sources (including websites, policy documents, and interviews) shows that the emergence of DTC gene testing is a conspicuous instance of co-production: a new kind of genetic knowledge and a new kind of biological citizenship is being articulated around the figure of the genetic consumer.",
keywords = "analytic validity, clinical utility, clinical validity, direct-to-consumer, genetic testing",
author = "Margaret Curnutte and Giuseppe Testa",
year = "2012",
month = "6",
day = "1",
doi = "10.1080/14636778.2012.662032",
language = "English",
volume = "31",
pages = "159--181",
journal = "New Genetics and Society",
issn = "1463-6778",
publisher = "Routledge",
number = "2",

}

TY - JOUR

T1 - Consuming genomes

T2 - Scientific and social innovation in direct-to-consumer genetic testing

AU - Curnutte, Margaret

AU - Testa, Giuseppe

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Since 2006 companies in the US have started to offer direct-to-consumer (DTC) genetic testing for a variety of diseases and traits. Recently, the activities of 23andMe and Navigenics, the two leading providers of DTC genetic services, have come under the scrutiny of various regulators and institutions, including the Food and Drug Administration (FDA) and the House Committee on Energy and Commerce and, in 2008, the California and New York Departments of Health. In this work we first situate this DTC innovation within the historical trajectory of gene testing as it developed in the context of clinical medicine around the three key criteria of analytic validity, clinical validity, and clinical utility. We then analyze the recent encounters between DTC providers and regulators to identify the key scientific and discursive resources that are being employed to position this innovation with respect to analytic validity, clinical validity, and clinical utility. Our empirical analysis of a rich set of primary sources (including websites, policy documents, and interviews) shows that the emergence of DTC gene testing is a conspicuous instance of co-production: a new kind of genetic knowledge and a new kind of biological citizenship is being articulated around the figure of the genetic consumer.

AB - Since 2006 companies in the US have started to offer direct-to-consumer (DTC) genetic testing for a variety of diseases and traits. Recently, the activities of 23andMe and Navigenics, the two leading providers of DTC genetic services, have come under the scrutiny of various regulators and institutions, including the Food and Drug Administration (FDA) and the House Committee on Energy and Commerce and, in 2008, the California and New York Departments of Health. In this work we first situate this DTC innovation within the historical trajectory of gene testing as it developed in the context of clinical medicine around the three key criteria of analytic validity, clinical validity, and clinical utility. We then analyze the recent encounters between DTC providers and regulators to identify the key scientific and discursive resources that are being employed to position this innovation with respect to analytic validity, clinical validity, and clinical utility. Our empirical analysis of a rich set of primary sources (including websites, policy documents, and interviews) shows that the emergence of DTC gene testing is a conspicuous instance of co-production: a new kind of genetic knowledge and a new kind of biological citizenship is being articulated around the figure of the genetic consumer.

KW - analytic validity

KW - clinical utility

KW - clinical validity

KW - direct-to-consumer

KW - genetic testing

UR - http://www.scopus.com/inward/record.url?scp=84862167712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862167712&partnerID=8YFLogxK

U2 - 10.1080/14636778.2012.662032

DO - 10.1080/14636778.2012.662032

M3 - Article

VL - 31

SP - 159

EP - 181

JO - New Genetics and Society

JF - New Genetics and Society

SN - 1463-6778

IS - 2

ER -